Essential Science

Hartley Wintney & Edzell, UK 1 April 2007 - Fleet Bioprocessing Ltd and Essential Science announce their continued collaboration around the development and commercialisation of Fleet's protein conjugation technologies within the European Life Science marketplace. Ongoing activities include evaluation of the emerging market for existing and novel cytotoxins for use in antibody-drug conjugates. Fleet are internationally recognised experts in the field of protein conjugation with extensive experience in all aspects of conjugate development and manufacture. This expertise positions Fleet to become an important player in the emerging immunoconjugate market.

About Fleet

Fleet BioProcessing specialises in developing processes for conjugating haptens, proteins and other materials to antibodies and other proteins. Historically the company has focused much of its effort and business results in exploiting its expertise in the diagnostics market. Fleet recognises the opportunity to exploit its expertise in the therapeutic market with particular reference to therapeutic Antibody conjugates.

www.fleetbioprocessing.co.uk

About Essential Science

Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.

Enquiries :: Neil Murray :: +44 1356 648941 :: neil@essentialscience.co.uk

Date :: Sunday 01 April 2007